NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage antiviral drug developer, announced that independent analyst Robert LeBoyer of Noble Capital Markets has initiated research coverage with an “Outperform” rating and a $6.00 price target. The report reviews the company’s lead programs, including its broad-spectrum antiviral candidate NV-387, along with longer-term development initiatives. NanoViricides noted that while it provided publicly available information and answered technical questions, the analyst independently developed all estimates, financial models and projections.
Separately, the company announced that President and Executive Chairman Anil R. Diwan participated in a “Fireside Chat” published by StockInvestor Daily’s IPO-Edge program, where he discussed NanoViricides’ antiviral technology platform, the potential of NV-387 against multiple viral diseases and variants, the company’s regulatory progress, including FDA Orphan Drug Designation and its Rare Pediatric Disease Designation filing for measles, as well as the resurgence of infectious diseases such as measles, mpox and Ebola.
The initiation of coverage by Noble Capital Markets signals growing investor interest in NanoViricides’ novel approach to antiviral therapy. The company’s nanoviricide technology, based on intellectual property from TheraCour Pharma, Inc., aims to create special purpose nanomaterials that can target a wide range of viruses. NV-387, the lead drug candidate, is being developed as a broad-spectrum antiviral for respiratory viral infections including RSV, COVID-19, Long COVID, Influenza, as well as MPOX/Smallpox and Measles.
This news is important because it underscores the potential of NanoViricides’ platform to address multiple viral threats, which is particularly relevant given the resurgence of infectious diseases like measles, mpox, and Ebola. The analyst’s $6 price target suggests significant upside from current trading levels, reflecting confidence in the company’s pipeline and regulatory progress. The FDA Orphan Drug Designation and Rare Pediatric Disease Designation filing for measles highlight the company’s strategic focus on underserved areas.
NanoViricides is advancing NV-387 toward Phase II human clinical trials. The company also has other drug candidates, including NV-CoV-2 for COVID-19 and NV-CoV-2-R, which encapsulates remdesivir. The company believes that since remdesivir is already FDA approved, NV-CoV-2-R could be an approvable drug if safety is comparable. However, the company cautions that drug development is lengthy and capital-intensive, and there is no assurance of success.
For more information on NanoViricides, visit their newsroom at https://ibn.fm/NNVC. The full press release is available at https://ibn.fm/7XBbY.
